Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijd.15622 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Rare delayed hypersensitivity reactions to contrast media: Severe cutaneous adverse reactions.
Eur J Radiol
December 2024
Allergy Unit, Allergo-Anaesthesia Unit, Hospital Universitario de la Cruz Roja, Madrid, Spain.
The risk of developing a severe delayed cutaneous reaction (SCAR) is very low following iodine-based contrast medium (ICM) administration and extremely low following gadolinium-based contrast agent (GBCA) administration. However, SCAR can be very severe and potentially life-threatening. It is crucial for the imaging physician to recognize danger signals: bullous skin eruption, skin erosion and detachment, mucosal involvement, systemic symptoms, and laboratory abnormalities.
View Article and Find Full Text PDFCase report: Toxic epidermal necrolysis induced by tislelizumab in a patient with esophageal squamous cell carcinoma.
Front Med (Lausanne)
December 2024
Department of Oncology, Ganzhou People's Hospital, Ganzhou, China.
Background: Immune checkpoint inhibitors (ICIs) have been widely applicated for the treatment of patients with advanced esophageal cancer. Skin-related adverse reactions are frequent with ICIs, with toxic epidermal necrolysis (TEN) being a severe and potentially life-threatening cutaneous reaction.
Case Presentation: We present a case of a 70-year-old male with locally advanced esophageal cancer who developed severe toxic epidermal necrolysis (TEN) after 18 days of tislelizumab combined with chemotherapy.
Analysis of real-world safety, tolerability, and cost efficiency of Sub-Cutaneous administration of Daratumumab in Manitoba.
J Oncol Pharm Pract
January 2025
CancerCare Manitoba, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.
Introduction: Daratumumab is an anti-CD38 monoclonal antibody used in the treatment of myeloma and other related disorders. To mitigate the risk of infusion related reactions with IV Daratumumab the product monograph suggested a slow administration schedule that extends over several hours. This leads to a significant burden for the outpatients' treatment administration units and indirect costs to the patients such as time toxicity.
View Article and Find Full Text PDFOral Antibiotics and Cutaneous Adverse Drug Reactions-Reply.
JAMA
January 2025
Division of General Internal Medicine and Clinical Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
Oral Antibiotics and Cutaneous Adverse Drug Reactions.
JAMA
January 2025
Department of Clinical and Environmental Allergology, Jagiellonian University Medical College, Kraków, Poland.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!